https://gsk2334470inhibitor.co....m/molecular-simulati
2020 Annals of Translational Drug. All rights reserved.Background The management of calcineurin inhibitors (CNIs) posttransplant happens to be implicated as an independent threat factor for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). The new immunosuppressive agent sirolimus (SRL) acts as a primary immunosuppressant or antitumor agent. In this study we investigated the consequence of sirolimus-based immunosuppression in comparison to CNIs
Like
Comment
Share
